• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The KRAS crowd targets its next cancer mutations.

作者信息

Mullard Asher

出版信息

Nat Rev Drug Discov. 2023 Mar;22(3):167-171. doi: 10.1038/d41573-023-00015-x.

DOI:10.1038/d41573-023-00015-x
PMID:36690752
Abstract
摘要

相似文献

1
The KRAS crowd targets its next cancer mutations.KRAS研究团队瞄准了下一批癌症突变。
Nat Rev Drug Discov. 2023 Mar;22(3):167-171. doi: 10.1038/d41573-023-00015-x.
2
Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.福尔马林固定石蜡包埋结直肠癌组织中RAS突变检测的靶向二代测序验证：与桑格测序及ARMS-蝎尾状探针实时PCR的比较
BMJ Open. 2016 Jan 8;6(1):e009532. doi: 10.1136/bmjopen-2015-009532.
3
The current understanding on the impact of KRAS on colorectal cancer.目前对 KRAS 对结直肠癌影响的理解。
Biomed Pharmacother. 2021 Aug;140:111717. doi: 10.1016/j.biopha.2021.111717. Epub 2021 May 24.
4
Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.整合组学分析揭示结直肠癌细胞中KRAS和BRAF突变的常见及突变特异性表型。
J Exp Clin Cancer Res. 2021 Jul 7;40(1):225. doi: 10.1186/s13046-021-02025-2.
5
Kirsten Ras* oncogene: significance of its discovery in human cancer research.Kirsten Ras* 癌基因：其在人类癌症研究中发现的意义
Oncotarget. 2016 Jul 19;7(29):46717-46733. doi: 10.18632/oncotarget.8773.
6
Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.结直肠癌肺转移患者 RAS 突变的意义。
Int J Clin Oncol. 2020 Apr;25(4):641-650. doi: 10.1007/s10147-019-01582-z. Epub 2019 Nov 26.
7
Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.中国Ib期肺腺癌患者的并发癌基因突变谱
Medicine (Baltimore). 2014 Dec;93(29):e296. doi: 10.1097/MD.0000000000000296.
8
RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.越南结直肠癌中不同通路的 RAS/RAF 突变及其与表观遗传改变的关联。
Pathol Res Pract. 2020 Apr;216(4):152898. doi: 10.1016/j.prp.2020.152898. Epub 2020 Feb 17.
9
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.转移性结直肠癌患者中 RAS 突变的流行情况和个体变异模式：随机对照试验的汇总分析。
Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3.
10
Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.结直肠癌患者突变状态、RAS 通路信号分子表达与临床病理特征和预后的关系。
World J Gastroenterol. 2019 Feb 21;25(7):808-823. doi: 10.3748/wjg.v25.i7.808.

引用本文的文献

1
Discovery of KRAS(G12D) selective degrader ASP3082.KRAS（G12D）选择性降解剂ASP3082的发现。
Commun Chem. 2025 Aug 23;8(1):254. doi: 10.1038/s42004-025-01662-4.
2
Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.靶向“不可成药”的KRAS：胰腺癌治疗的突破、挑战与机遇
Cancer Biol Med. 2025 Jul 7. doi: 10.20892/j.issn.2095-3941.2025.0122.
3
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.细胞周期蛋白依赖性蛋白激酶与生物学和疾病中的细胞周期调控
Signal Transduct Target Ther. 2025 Jan 13;10(1):11. doi: 10.1038/s41392-024-02080-z.
4
Consensus, debate, and prospective on pancreatic cancer treatments.胰腺癌治疗的共识、争议与展望。
J Hematol Oncol. 2024 Oct 10;17(1):92. doi: 10.1186/s13045-024-01613-x.
5
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.评估KRAS抑制剂导向疗法用于胰腺癌治疗的效果。
Front Oncol. 2024 May 10;14:1402128. doi: 10.3389/fonc.2024.1402128. eCollection 2024.
6
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development.将GAP与RAS突变体结合：癌症药物开发中一个老问题的新方法。
Int J Mol Sci. 2024 Feb 22;25(5):2572. doi: 10.3390/ijms25052572.
7
Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.跨物种比较泛 RAF 抑制剂 LY3009120 在马、犬和人恶性黑素瘤细胞系中的抗肿瘤作用。
Genes (Basel). 2024 Feb 3;15(2):202. doi: 10.3390/genes15020202.
8
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in -mutant cancers.小分子抑制 MAP2K4 与 RAS 抑制剂在 - 突变型癌症中具有协同作用。
Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2319492121. doi: 10.1073/pnas.2319492121. Epub 2024 Feb 20.
9
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.抑制胰腺癌中的 RAF/MEK/ERK 信号级联：最新进展与未来展望。
Int J Mol Sci. 2024 Jan 28;25(3):1631. doi: 10.3390/ijms25031631.
10
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.针对 KRAS 突变衍生抗原的免疫治疗策略的事实与展望。
Clin Cancer Res. 2024 May 15;30(10):2017-2024. doi: 10.1158/1078-0432.CCR-23-1212.